Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This report describes a case of a woman with ophiasis-pattern alopecia areata who experienced significant hair regrowth and maintained it for 6 months after treatment with dupilumab, though she eventually relapsed.

This narrative review suggests that while corticosteroids and Janus kinase inhibitors may be effective for treating ophiasis-pattern alopecia areata in both adults and children, the limited age-specific evidence underscores the need for further research to confirm their efficacy and safety across age groups.

This study suggests that young females may experience a rare coexistence of Frontal Fibrosing Alopecia and ophiasis pattern Alopecia Areata, possibly sharing a common underlying pathophysiology.

In this report, a young Caucasian woman developed a hairy tongue as an unusual side effect during baricitinib therapy for severe alopecia areata, which was managed by daily toothbrush debridement.

This case report describes a four-month-old infant with atypical alopecia areata following a cultural head-shaving ritual, who showed improvement with topical triamcinolone treatment, though not full symptom resolution, highlighting the rarity and complexity of managing AA in infants.

In this case study, the authors explored the management of ophiasis, a rare and challenging form of alopecia areata, in a 3-year-old boy using the Unani system of medicine, aiming to provide insights for treatment approaches.

This case report describes a 21-year-old man with alopecia areata presenting as a U-shaped hair loss pattern resembling Hamilton grade VII male-pattern baldness, with no signs of inflammation or related conditions.

A man had an unusual type of hair loss that didn't match known patterns and didn't improve with treatment.

In this case report, the authors describe a child with treatment-resistant alopecia areata who successfully responded to leflunomide and anthralin, proposing this combination as a potentially cost-effective alternative for managing recalcitrant cases by possibly inhibiting the JAK/STAT pathway.

A girl with Crohn's disease developed hair loss from her medication, which improved with treatment but later returned.

This study found that, among 100 patients with alopecia areata, the most prevalent subtype was patchy alopecia areata, with characteristic trichoscopic features including black dots, yellow dots, and empty hair follicles.

This study reported that low serum ferritin levels in pediatric patients with alopecia areata were associated with increased disease severity and longer duration.

This chapter reviews alopecia areata treatments, highlighting factors like age and disease extent in choosing management strategies, but reports no new clinical findings.

This paper discusses alopecia areata, its autoimmune nature, factors influencing susceptibility, diagnostic challenges, and treatment limitations, concluding that no current therapy is curative or preventive; it reports no new clinical results.

In this study, a patient with severe alopecia areata showed significant hair regrowth after 15 months of partial response to baricitinib and oral minoxidil, following the addition of dupilumab to their treatment regimen.

This report presents a rare case of discoid lupus erythematosus in a Saudi woman, highlighting the need for dermatologists to recognize atypical presentations to prevent misdiagnosis and treatment delays.

This study found that topical clobetasol propionate cream provided a modest improvement in hair regrowth for alopecia areata patients, though those with atopy had higher relapse rates after treatment completion.

This case report describes a 58-year-old man with ophiasis-pattern alopecia areata who showed significant hair regrowth after treatment with clobetasol and microneedling with triamcinolone.

In this case study, a 5-year-old girl with alopecia areata and atopic dermatitis that were unresponsive to previous treatments achieved substantial improvement with long-term tofacitinib, highlighting its potential safety and efficacy in managing both conditions concurrently.

This study introduces "alopecia areata in a male or female pattern distribution" as a new clinical subtype of alopecia areata, observed in three adult cases, to enhance diagnostic precision and treatment personalization.

This review of alopecia areata cases at Virgen Macarena University Hospital identified a new hair regrowth pattern they term "androgenetic alopecia type" and described a unique inverse form called "sisaipho type" in three cases.

In this case report, secukinumab therapy for spondyloarthritis was associated with the development of alopecia areata in a 46-year-old woman, which improved after discontinuing the medication.

In this report, researchers documented a rare complication linked to levofloxacin, used as a second-line treatment for tuberculosis, which could include various adverse events during TB therapy.

This study found that patients with alopecia areata often presented with multilocular patches, common scalp involvement, and associated conditions like atopic dermatitis; the disease predominantly affected younger individuals.

This report describes five cases of bitemporal alopecia areata with frontal hairline involvement, detailing their management strategies and highlighting potential differential diagnoses, but does not present new clinical results.

In this study, researchers characterized the clinical features of ophiasis, an uncommon type of alopecia areata, and proposed a new subtype classification that may help predict treatment response and guide management, noting that ophiasis generally has a chronic and refractory nature.

The authors discuss that hair loss affecting the occipital scalp is understudied and may be caused by factors like movement irritation and clothing occlusion; this lack of data can lead to missed diagnoses and inadequate treatment.

In this review, researchers examined current knowledge on alopecia areata, finding it affects approximately 2% of individuals, with a likely autoimmune and genetic basis, and highlighting its association with other medical and psychiatric conditions, although no cure currently exists.

In this case study, a 10-year-old girl with infantile ophiastic alopecia areata and ciliary madarosis showed excellent hair and eyelash regrowth after 56 days of treatment involving oral corticosteroids, topical minoxidil, and clobetasol hair lotion, following an initial diagnosis and psychological evaluation.

This review of real-world treatment options for AA indicates that current therapies are insufficient, with high dissatisfaction rates, highlighting a need for improved solutions.